Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

285
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
285
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

205
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
205
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

435
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
435
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

166
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
166
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

354
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lower adherence to healthy lifestyle is associated with increased adiposity and cardiovascular risk in youth.

Frontiers in nutrition·2026
Same author

Infantile GM1 Gangliosidosis with Epilepsy Associated with a Same-Codon GLB1 Variant (c.808T>G/c.808T>C).

Genes·2026
Same author

Technology-Based Interventions for Physical Activity and Sedentary Behaviour in Adults: A Scoping Review.

Journal of functional morphology and kinesiology·2026
Same author

Sport Participation and Nutrition in Students: A Scoping Review of Neuroendocrine and Autonomic Mechanisms Linking Lifestyle Behaviors to Cognitive and Academic Outcomes.

Nutrients·2026
Same author

The Gut Microbiota-Polyphenol-NLRP3 Inflammasome Axis: A Key Regulatory Network Linking Diet to Chronic Inflammation.

Nutrients·2026
Same author

Beyond Suicidal Ideation: Identifying High-Risk University Students Through Depression, Sleep Disturbance, and Impulsivity-A Cross-Sectional Secondary Analysis.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jul 29, 2025

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

11.5K

Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders.

Rosa Savino1, Anna Nunzia Polito1, Gabriella Marsala2

  • 1Department of Woman and Child, Neuropsychiatry for Child and Adolescent Unit, General Hospital "Riuniti" of Foggia, 71122 Foggia, Italy.

Brain Sciences
|May 27, 2023
PubMed
Summary

Agomelatine (AGM), a novel antidepressant, shows potential for treating neurological developmental disorders like ADHD and ASD. Its unique action on circadian rhythms and neurotransmitters may improve cognition and neuronal plasticity in children and adolescents.

Keywords:
AGMattention deficit hyperactivity disorder (ADHD)autism spectrum disorder (ASD)melatonin agonist and selective serotonin antagonist (MASS)neurodevelopmental disorders

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.4K

Related Experiment Videos

Last Updated: Jul 29, 2025

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

11.5K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Developmental Disorders

Background:

  • Agomelatine (AGM) is an atypical antidepressant.
  • It functions as a melatonin receptor agonist and serotonin receptor antagonist.
  • Current use is limited to adult depression due to scarce pediatric data.

Purpose of the Study:

  • To review the potential of Agomelatine in neurological developmental disorders.
  • To explore AGM's role in conditions like ADHD and ASD.
  • To assess its suitability for pediatric populations.

Main Methods:

  • Review of existing studies and case reports on Agomelatine.
  • Analysis of AGM's pharmacological mechanisms.
  • Evaluation of its effects on neurotransmission and neuronal plasticity.

Main Results:

  • AGM may enhance cytoskeleton-associated protein (ARC) expression, improving learning and memory.
  • It modulates glutamatergic neurotransmission, impacting mood and cognition.
  • AGM acts as an antidepressant, psychostimulant, and promotes neuronal plasticity.

Conclusions:

  • Agomelatine demonstrates potential for treating autism spectrum disorder (ASD) and attention deficit and hyperactivity disorder (ADHD).
  • Its ability to resynchronize circadian rhythms and improve cognitive function is promising.
  • Good tolerability suggests potential for adolescent and pediatric use.